A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor

References

• Bezjak A, Paulus R, Gaspar L, Timmerman R, Straube W, Ryan W, Garces Y, Pu A, Singh A, Videtic G. 2016. Efficacy and toxicity analysis of NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol. 96:S8.
   Google Scholar
• Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, et al. 2015. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16:187–199.
   PubMed Web of Science ®Google Scholar
• Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJM, McRae SE, Widder J, Feng L, et al. 2015. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 16:630–637.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, Hara WY, Trakul N, Loo BW, Jr, Diehn M. 2015. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer. 89:50–56.
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Haas AR, Rengan R. 2012. Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med. 366:2327–2329.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
   PubMed Web of Science ®Google Scholar
• Gomez-Caro A, Garcia S, Reguart N, Cladellas E, Arguis P, Sanchez M, Gimferrer JM. 2011. Determining the appropriate sleeve lobectomy versus pneumonectomy ratio in central non-small cell lung cancer patients: an audit of an aggressive policy of pneumonectomy avoidance. Eur J Cardiothorac Surg. 39:352–359.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, Sauer O, Deutschen Gesellschaft fur Radioonkologie (DEGRO). 2014. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 190:26–33.
   PubMed Web of Science ®Google Scholar
• Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 2011. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 6:2036–2043.
   PubMed Web of Science ®Google Scholar
• Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, Yorke ED, Wu AJ. 2016. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 6:e27–e33.
   PubMed Web of Science ®Google Scholar
• Huber RM, Fischer R, Hautmann H, Pöllinger B, Häußinger K, Wendt T. 1997. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys. 38:533–540.
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Kim E-Y, Ban H-J, Oh I-J, Kim K-S, Kim Y-C, Ahn S-J. 2010. Risk factors for fatal hemoptysis after concurrent chemoradiation therapy in patients with non-small cell lung carcinoma. Chonnam Med J. 46:19–24.
   Google Scholar
• Langendijk JA, Tjwa MK, de Jong JM, ten Velde GP, Wouters EF. 1998. Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor? Radiother Oncol. 49:175–183.
   PubMed Web of Science ®Google Scholar
• Ma QL, Guo YQ, Shi B, Tian YC, Song ZY, Liu DR. 2016. For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy? J Thorac Dis. 8:1227–1233.
   PubMed Web of Science ®Google Scholar
• National Cancer Comprehensive Network (NCCN). 2018. Principles of radiation therapy (NSCL-C), Non-small cell lung cancer. NCCN Guidelines Version 4. [accessed 2019 January 15]. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, et al. 2007. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2:S94–S100.
   PubMed Web of Science ®Google Scholar
• Rim CH, Kim Y, Kim CY, Yoon WS, Yang DS. 2019. Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis. Int J Radiat Biol. 95:329–337.
   PubMed Web of Science ®Google Scholar
• Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, Hashemi S, Nossent E, Spoelstra F, de Langen AJ, et al. 2016. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with "Ultracentral" non-small cell lung cancer. J Thorac Oncol. 11:1081–1089.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Hu C, Michalski J, Straube W, Galvin J, Johnstone D, Bradley J, Barriger R, Bezjak A, Videtic G. 2014. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Biol. 90:S30.
   Google Scholar
• Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, et al. 2018. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 Trial. JAMA Oncol. 4:1263–1266.
   PubMed Web of Science ®Google Scholar
• Yu T, Shin I, Yoon WS, Rim CH. 2019. Stereotactic body radiotherapy for centrally located primary non-small cell lung cancer: a meta-analysis. Clin Lung Cancer. pii: S1525-7304(19)30073-7.
   Web of Science ®Google Scholar